written on 21.05.2014
Tags:
,

Second-line use, crowded market won't keep Takeda's Entyvio from blockbuster run

TAGS: ,

Takeda is finally over the hump with its inflammatory bowel disease drug Entyvio after safety questions threatened its approval. And while the drug will take a backseat to some of the market's heavyweights, some analysts say that won't stop it from hitting the blockbuster mark itself.

Latest Report